Page last updated: 2024-10-19

niacinamide and Skin Aging

niacinamide has been researched along with Skin Aging in 25 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Skin Aging: The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.

Research Excerpts

ExcerptRelevanceReference
"We demonstrated that post-laser topical application of ADSC-CM in combination with niacinamide has anti-aging effect on skin."9.41Randomized controlled study for the anti-aging effect of human adipocyte-derived mesenchymal stem cell media combined with niacinamide after laser therapy. ( Chung, KB; Kim, J; Kim, S; Lee, JH; Lee, YI, 2021)
" This formulation also features niacinamide and terminalia chebula to further support the anti-aging benefits of retinol."8.12Facial Aging Improvement Case Study Using a Novel Combination of Retinol, Niacinamide, and Terminalia Chebula. ( Adams-Woodford, A; Ayres, P; Diaz, I; Giancola, G; Handler, M, 2022)
"We demonstrated that post-laser topical application of ADSC-CM in combination with niacinamide has anti-aging effect on skin."5.41Randomized controlled study for the anti-aging effect of human adipocyte-derived mesenchymal stem cell media combined with niacinamide after laser therapy. ( Chung, KB; Kim, J; Kim, S; Lee, JH; Lee, YI, 2021)
" This formulation also features niacinamide and terminalia chebula to further support the anti-aging benefits of retinol."4.12Facial Aging Improvement Case Study Using a Novel Combination of Retinol, Niacinamide, and Terminalia Chebula. ( Adams-Woodford, A; Ayres, P; Diaz, I; Giancola, G; Handler, M, 2022)
"Moreover, NAM reduces skin cancer incidence and prevents the immune-suppressive effects of UV in mice."2.61Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention. ( Abeni, D; Campione, E; Candi, E; Dellambra, E; Fania, L; Mazzanti, C, 2019)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (20.00)29.6817
2010's11 (44.00)24.3611
2020's9 (36.00)2.80

Authors

AuthorsStudies
Tan, CYR2
Tan, CL2
Chin, T2
Morenc, M1
Ho, CY1
Rovito, HA2
Quek, LS2
Soon, AL1
Lim, JSY1
Dreesen, O1
Oblong, JE3
Bellanger, S2
Mahajan, AS1
Arikatla, VS1
Thyagarajan, A1
Zhelay, T1
Sahu, RP1
Kemp, MG1
Spandau, DF1
Travers, JB1
Rani, S1
Banik, KB1
Rath, S1
Handler, M1
Adams-Woodford, A1
Ayres, P1
Giancola, G1
Diaz, I1
Voegeli, R1
Campiche, R2
Biassin, R1
Rawlings, AV1
Shackelford, TK1
Fink, B1
Fania, L1
Mazzanti, C1
Campione, E1
Candi, E1
Abeni, D1
Dellambra, E1
Curpen, SJ1
Lutchmanen-Kolanthan, V1
Gougeon, S1
Cherel, M1
Laurent, G1
Gempeler, M1
Schuetz, R1
Lee, YI1
Kim, S1
Kim, J2
Chung, KB1
Lee, JH1
Flagler, MJ1
Tamura, M1
Laughlin, T1
Hartman, S1
Ashe, J1
Adams, R1
Kozak, K1
Cresswell, K1
Mullins, L1
Jarrold, BB1
Isfort, RJ1
Sherrill, JD1
Nisbet, S1
Mahalingam, H1
Gfeller, CF1
Biggs, E1
Lucas, S1
Thompson, M1
Cargill, MR1
Moore, D1
Bielfeldt, S1
Snaidr, VA1
Damian, DL2
Halliday, GM1
Osborne, R1
Carver, RS1
Mullins, LA1
Finlay, DR1
Chen, AC1
Berardesca, E1
Ardigo, M1
Cameli, N1
Mariano, M1
Agozzino, M1
Matts, PJ1
Escudero-Góngora, MM1
Fernández-Peñas, P1
Farris, P1
Zeichner, J1
Berson, D1
Barros, BS1
Zaenglein, AL1
Kawada, A1
Konishi, N1
Oiso, N1
Kawara, S1
Date, A1
Kaczvinsky, JR2
Griffiths, CE1
Schnicker, MS1
Li, J2
Fu, JJ1
Hillebrand, GG1
Raleigh, P1
Marmor, MJ1
Bertucci, V1
Grimes, PE1
Mandy, SH1
Perez, MI1
Weinkle, SH1
Bissett, D1
Bissett, DL1
Berge, CA1
Chiu, PC1
Chan, CC1
Lin, HM1
Chiu, HC1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Proof of Concept (POC) Clinical Study to Evaluate the Appearance of Fine Lines and Wrinkles on a Developmental Cosmetic Moisturising Cream in Healthy Subjects Presenting Visible Signs of Ageing[NCT03180645]72 participants (Actual)Interventional2017-03-20Completed
A Proof of Concept (POC) Clinical Study to Investigate the Effects of a Developmental Cosmetic Moisturising Cream on the Barrier Function of Human Skin on the Face and Forearm[NCT03216265]69 participants (Actual)Interventional2017-02-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29

Using fringe projection and optical triangulation techniques, the 3D (three dimensional) surface structure of a designated investigational skin site on each side of the face was captured as an in vivo measurement using dermaTOP. From the captured 3D structure, roughness parameters were calculated. Ra is usually used for wrinkle assessments, representing the finer skin structure (Ra). Ra was the average deviation of the profile from the mean line (arithmetic mean of the absolute values of the point's heights). (NCT03180645)
Timeframe: At Baseline and Day 29

InterventionMicro meter (µm) (Mean)
Test Product-1.90
No Treatment-0.12

Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated vs. Untreated Side at Day 15

Using fringe projection and optical triangulation techniques, the 3D surface structure of a designated investigational skin site on each side of the face was captured as an in vivo measurement using dermaTOP. From the captured 3D structure, roughness parameters were calculated. Ra is usually used for wrinkle assessments, representing the finer skin structure (Ra). Ra was the average deviation of the profile from the mean line (arithmetic mean of the absolute values of the point's heights). (NCT03180645)
Timeframe: At Baseline and Day 15

Interventionµm (Mean)
Test Product-0.65
No Treatment-0.18

Percent Improvement From Baseline in Skin Texture Rankings Based on Lay Grader Assessment of High Resolution Images at Day 29

High resolution images of the left and right side of each participant's whole half-face were taken at baseline and Day 29. Each blinded image pair was randomly displayed on a color-calibrated screen and assessed by a panel of lay graders, who ranked each image based on texture, defined as pores, smoothness and unevenness, on a scale of: 1 = better; or 2 = worse (lower score indicated improvement). The total proportion of improvement (from all lay graders) on Day 29 than baseline is reported for this endpoint. (NCT03180645)
Timeframe: At Baseline and Day 29

InterventionPercent of improvement ratings (Number)
Test Product41.49
Positive Control39.54
Negative Control40.58

Change From Baseline in Clinical Fitzpatrick Wrinkle Score, at Day 15 and 29

A blinded, trained and qualified examiner performed Clinical Fitzpatrick Wrinkle Score assessments by visually grading the crow's feet area under standard conditions of illumination. Fitzpatrick Wrinkle Scores range between 1-9 where 1-3= Fine wrinkles, 4-6= Fine to moderate depth wrinkles, a moderate number of wrinkles, 7-9= Fine to deep wrinkles, numerous lines, with or without redundant skin folds. Low value indicated better results. (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,,
InterventionScore on a scale (Mean)
Day 15Day 29
No Treatment-0.15-0.22
Positive Control-0.28-0.58
Test Product-0.33-0.51

Change From Baseline in Instrumental Corneometer Values, at Day 15 and 29

Measurement of Stratum Corneum (SC) hydration was performed by the electrical capacitance method with a Corneometer. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. An electric field was created between gold conductors to enable the dielectricity of the SC to be measured. Because the dielectricity varies as a function of the skin's water content, the SC moisturisation was measured. Higher value of corneometery indicates high moisture content. (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,,
InterventionInstrumental units (I.U) (Mean)
Day 15Day 29
No Treatment-1.091.62
Positive Control7.1310.03
Test Product6.128.30

Change From Baseline in Instrumental Cutometer Parameter R7, at Day 15 and 29

The Cutometer measures elasticity of the upper skin layer using negative pressure which deforms the skin mechanically. Negative pressure was created in the device and the skin was drawn into the aperture of the probe and after a defined time released again. Inside the probe, the penetration depth was determined by a non-contact optical measuring system. The light intensity varies due to the penetration depth of the skin. The resistance of the skin to the negative pressure (firmness) and its ability to return into its original position (elasticity) are displayed as curves (penetration depth in mm/time) in real time during the measurement. This measurement principle provides information about the elastic and mechanical properties of the skin surface and enables objective quantification of skin ageing. R7: Portion of the elasticity compared to the complete curve values. (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,,
InterventionRatio (unitless) (Mean)
Day 15Day 29
No Treatment-0.030.02
Positive Control0.010.02
Test Product0.020.03

Change From Baseline in Instrumental Cutometer Parameters R5, at Day 15 and 29

The Cutometer measures elasticity of the upper skin layer using negative pressure which deforms the skin mechanically. Negative pressure was created in the device and the skin was drawn into the aperture of the probe and after a defined time released again. Inside the probe, the penetration depth was determined by a non-contact optical measuring system. The light intensity varies due to the penetration depth of the skin. The resistance of the skin to the negative pressure (firmness) and its ability to return into its original position (elasticity) was displayed as curves (penetration depth in mm/time) in real time during the measurement. This measurement principle provides information about the elastic and mechanical properties of the skin surface and enables objective quantification of skin ageing. R5 (net elasticity): the elastic portion of the suction part versus the elastic portion of the relaxation part. (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,,
InterventionRatio (unitless) (Mean)
Day 15Day 29
No Treatment-0.050.03
Positive Control0.010.05
Test Product0.050.08

Change From Baseline in Ra (a dermaTOP Parameter), of Positive Control Treated vs. Untreated Side at Day 15 and 29

Using fringe projection and optical triangulation techniques, the 3D surface structure of a designated investigational skin site on each side of the face was captured as an in vivo measurement using dermaTOP. From the captured 3D structure, roughness parameters were calculated. Ra is usually used for wrinkle assessments, representing the finer skin structure (Ra). Ra is the average deviation of the profile from the mean line (arithmetic mean of the absolute values of the point's heights). (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,
Interventionµm (Mean)
Day 15Day 29
No Treatment-0.18-0.12
Positive Control0.18-0.13

Change From Baseline in Rz (a dermaTOP Parameter) at Day 15 and 29

Using fringe projection and optical triangulation techniques, the 3D surface structure of a designated investigational skin site on each side of the face was captured as an in vivo measurement using dermaTOP. From the captured 3D structure, roughness parameters were calculated. Rz usually used for wrinkle assessments, representing the rough structure, such as wrinkles. Rz was an average of the 5 sub-profiles (peak to valley heights) local maximum. From each local profile the peak to peak height value is calculated; the average of the 5 peak to peak height values was Rz. (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,,
Interventionµm (Mean)
Day 15Day 29
No Treatment-1.46-1.08
Positive Control0.97-0.55
Test Product-1.92-7.01

Change From Baseline in Sa (dermaTOP Parameters) at Day 15 and 29

Using fringe projection and optical triangulation techniques, the 3D surface structure of a designated investigational skin site on each side of the face was captured as an in vivo measurement using dermaTOP. The 3D skin surface profile was calculated from the position of the fringes in combination with the Gray values of each pixel. From the captured 3D structure, roughness parameters were calculated. Sa was the arithmetic average of the absolute (non- signed) heights of the topography points. Sa was the 3D Area -Equivalent of 2D profile roughness parameter Ra. (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,,
Interventionµm (Mean)
Day15Day 29
No Treatment-0.08-0.26
Positive Control0.17-0.21
Test Product-0.60-1.83

Change From Baseline in Stm (dermaTOP Parameters), at Day 15 and 29

Using fringe projection and optical triangulation techniques, the 3D surface structure of a designated investigational skin site on each side of the face was captured as an in vivo measurement using dermaTOP. The 3D skin surface profile was calculated from the position of the fringes in combination with the Gray values of each pixel. From the captured 3D structure, roughness parameters were calculated. Stm was an average of the 5x5 sub-areas (peak to valley heights) local maximum: The surface was virtually divided into 25 sub-surfaces (5 rows, 5 columns); from each local surface the peak to peak height value is calculated; the average of the 25 peak to height values was Stm. (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,,
Interventionµm (Mean)
Day 15Day 29
No Treatment-2.02-3.27
Positive Control5.350.23
Test Product5.81-12.89

Change From Baseline in Trans-Epidermal Water Loss (TEWL) at Day 15 and 29

TEWL measuring principle was based on water vapour gradient determination between two pairs of sensors (temperature and relative humidity) placed at different distances perpendicularly to the skin. Measurements were taken in triplicate and then an average (mean) reading was calculated on the left and right Sub-ocular/ Cheek Area directly from the corner of the eyes onto the middle of the cheekbone. A decrease in TEWL corresponds to an improved skin barrier function. (NCT03180645)
Timeframe: At Baseline, Day 15 and 29

,,
Interventiongram (g)/meter^2 (m)/hour (Mean)
Day 15Day 29
No Treatment-2.02-3.00
Positive Control-5.98-6.62
Test Product-4.17-5.18

Change From Baseline in Transepidermal Water Loss (TEWL) Measurements on Day 29 of Positive Control Treated Site vs. Untreated Site on the Forearm.

TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 seconds were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: At Baseline and Day 29

Interventiong/m^2/hour (Mean)
Positive Control-1.13
No Treatment0.79

Change From Baseline in Transepidermal Water Loss (TEWL) Measurements on Day 29, Test Product Treated Versus (vs.) Untreated Sites on the Forearm

TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 seconds (sec), to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: At Baseline and Day 29

Interventiongram (g)/meter(m)^2/hour (Mean)
Test Product-0.59
No Treatment0.79

Change From Baseline in Transepidermal Water Loss (TEWL) Measurements on Day 29, Test Product Treated vs. Untreated Sites on the Face

TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: At Baseline and Day 29

Interventiong/m^2/hour (Mean)
Test Product-4.33
No Treatment-3.18

Protein Analysis (SquameScan) of D-Squame Discs (Total of 12 Adhesive Discs) From Skin of Both Test Product Treated and Untreated Sites on the Forearm on Day 29

The protein content of each D-Squame disc was analysed using a SquameScan. SquameScan is the instrument used to indirectly measure the protein content extracted from the skin by D-squame tape strips. The determination was performed by measuring the optical absorption of the strip at about 850 nanometres (nm) (infrared light). The value displayed in % was proportionally related to the protein content. The protein content was analysed for each of the discs obtained the D-Squame stripping on the forearms and reported to 2 decimal places. (NCT03216265)
Timeframe: On Day 29

InterventionPercent (Mean)
Test Product173.16
No Treatment213.89

Protein Analysis of D-Squame Discs (Total of 9 Adhesive Discs) From Skin of Both Test Product Treated and Untreated Sites on the Face on Day 29

The protein content of each D-Squame disc was analysed using a SquameScan. SquameScan is the instrument used to indirectly measure the protein content extracted from the skin by D-squame tape strips. The determination was performed by measuring the optical absorption of the strip at about 850 nm (infrared light). The value displayed in % was proportionally related to the protein content. The protein content was analysed for each of the discs obtained the D-Squame stripping on the face and reported to 2 decimal places. (NCT03216265)
Timeframe: On Day 29

Interventionpercent of absorption (Mean)
Test Product84.70
No Treatment107.75

Change From Baseline in Corneometry Measurements on Days 30, 31, 32, 33 and 34 in Test Product Treated Site vs. Untreated Site on the Forearm and Face

Corneometry was used to measure the moisture content of stratum corneum using corneometer. The measuring principle is based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. The Corneometer measurements were taken 5 times in total and then an average reading was calculated for each site and time point. An increase in corneometry values indicates an increase in the hydration status of the skin and vice versa. (NCT03216265)
Timeframe: At Baseline, Day 30, 31, 32, 33, and 34

,
InterventionCorneometry units (Mean)
Day 30, change from baseline, forearmDay 31,change from baseline, forearmDay 32,change from baseline, forearmDay 33,change from baseline, forearmDay 34,change from baseline, forearmDay 30,change from baseline, faceDay 31,change from baseline, faceDay 32,change from baseline, faceDay 33,change from baseline, faceDay 34,change from baseline, face
No Treatment3.483.542.251.541.992.350.760.41-2.381.09
Test Product7.115.514.252.853.539.687.405.932.934.76

Change From Baseline in Corneometry on the Forearm and Face, Test Product Treated vs. Untreated Sites

Corneometry was used to measure moisture content of stratum corneum using corneometer. The measuring principle is based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. The Corneometer measurements was taken 5 times in total and then an average reading was calculated for each site and time point. An increase in corneometry values indicates an increase in the hydration status of the skin and vice versa. (NCT03216265)
Timeframe: At Baseline, Day 1 (30 minutes and 6 hours post study product application), Day 2, 15, and 29

,
InterventionCorneometry Units (Mean)
Day 1 (30 mins), change from baseline forearmDay 1 (6 hours), change from baseline, forearmDay 2, change from baseline, forearmDay 15, change from baseline, forearmDay 29, change from baseline, forearmDay 1 (30 mins) change from baseline, faceDay 1 (6 hours ), change from baseline, faceDay 2, change from baseline, faceDay 15, change from baseline, faceDay 29, change from baseline, face
No Treatment-3.24-0.341.483.064.50-6.96-1.90-0.452.503.81
Test Product14.2910.728.6512.0211.8525.1213.948.8813.9216.94

Change From Baseline in Standardised Area Under Curve (AUCday 29-34) of Transepidermal Water Loss (TEWL) Over Regression Period (Days 30, 31, 32, 33 and 34) of Forearm and Face, Test Product Treated vs. Untreated Sites

Standardised AUCday29-34 was calculated for each participant for change from baseline in TEWL on forearms and face over the regression period (Day31, 32, 33 and 34) using the trapezoidal rule and dividing by the number of days in the period. TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value was established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: Up to Day 34

,,
Interventiong/m^2/hour (Mean)
Change from baseline in AUCday29-34, forearmChange from baseline in AUCday29-34, face
No Treatment1.25-3.21
Positive Control-0.51-4.81
Test Product-0.54-3.94

Change From Baseline in Transepidermal Water Loss (TEWL) Measurements on Days 30, 31, 32, 33 and 34 in Test Product Treated vs. Untreated Sites on the Forearm and Face

TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value was established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: At Baseline, Day 30, 31, 32, 33 and 34

,
Interventiong/m^2/hour (Mean)
Day 30, Change from baseline, forearmDay 31, Change from baseline, forearmDay 32,Change from baseline, forearmDay 33,Change from baseline, forearmDay 34, Change from baseline, forearmDay 30, Change from baseline, faceDay 31, Change from baseline, faceDay 32, Change from baseline, faceDay 33, Change from baseline, faceDay 34, Change from baseline, face
No Treatment1.121.531.481.001.18-3.18-3.27-3.05-3.64-3.18
Test Product-0.37-0.77-0.17-0.42-0.59-4.40-4.26-3.27-3.52-3.52

Change From Baseline in Transepidermal Water Loss (TEWL) on the Forearm and Face, Test Product Treated vs. Untreated Sites at Day 2 and 15

TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: At Baseline, Day 2, and 15

,
Interventiong/m^2/hour (Mean)
Day 2, change from baseline, forearmDay 15, change from baseline, forearmDay 2, change from baseline, faceDay 15, change from baseline, face
No Treatment0.481.070.77-2.37
Test Product0.08-0.23-1.49-4.79

Change From Day 29 in Corneometry Measurements on Days 30, 31, 32, 33 and 34 in Test Product Treated Site vs. Untreated Site on the Forearm and Face

Corneometry was used to measure the moisture content of stratum corneum using corneometer. The measuring principle is based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. The Corneometer measurements were taken 5 times in total and then an average reading was calculated for each site and time point. An increase in corneometry values indicates an increase in the hydration status of the skin and vice versa. (NCT03216265)
Timeframe: At Day 29, 30, 31, 32, 33, and 34

,
InterventionCorneometry units (Mean)
Day 30, change from Day 29, forearmDay 31,change from Day 29, forearmDay 32,change from Day 29, forearmDay 33,change from Day 29, forearmDay 34,change from Day 29, forearmDay 30,change from Day 29, faceDay 31,change from Day 29, faceDay 32,change from Day 29, faceDay 33,change from Day 29, faceDay 34,change from Day 29, face
No Treatment-1.06-1.10-2.38-3.02-2.65-1.57-3.09-3.44-6.15-2.77
Test Product-4.44-6.37-7.72-8.63-8.43-7.84-9.59-11.28-14.22-12.45

Change From Day 29 in Standardised Area Under Curve (AUCday 29-34) of Transepidermal Water Loss (TEWL) Over Regression Period (Days 30, 31, 32, 33 and 34) of Forearm and Face, Test Product Treated vs. Untreated Sites

Standardised AUCday29-34 was calculated for each participant for change from Day 29 in TEWL on forearms and face over the regression period (Day31, 32, 33 and 34) using the trapezoidal rule and dividing by the number of days in the period. TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value was established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: Up to Day 34

,,
Interventiong/m^2/hour (Mean)
Change from Day 29 in AUCday29-34, forearmChange from Day 29 in AUCday29-34, face
No Treatment0.38-0.13
Positive Control0.660.38
Test Product0.130.51

Change From Day 29 in Transepidermal Water Loss (TEWL) Measurements on Days 30, 31, 32, 33 and 34 in Test Product Treated vs. Untreated Sites on the Forearm and Face

TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value was established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: At Day 30, 31, 32, 33, and 34

,
Interventiong/m^2/hour (Mean)
Day 30, change from Day 29, forearmDay 31, change from Day 29, forearmDay 32, change from Day 29, forearmDay 33, change from Day 29, forearmDay 34, change from Day 29, forearmDay 30, change from Day 29, faceDay 31, change from Day 29, faceDay 32, change from Day 29, faceDay 33, change from Day 29, faceDay 34, change from Day 29, face
No Treatment0.250.720.670.190.37-0.050.010.22-0.410.09
Test Product0.20-0.090.450.260.030.100.221.171.000.91

Change From Pre-challenge in Transepidermal Water Loss (TEWL) Measurements of D-Squame Discs Following 3, 6 and 9 Adhesive Discs Removal From Skin of Both Test Product Treated and Untreated Sites on the Face on Day 29

A series of D-Squame discs were gently smoothed over the designated D-Squame Areas by applying a uniform pressure for 5 secs with a stamp to ensure consistent adhesion to the skin. Each disc was pulled off the skin with one fluent and decisive movement. There were maximum of 9 D-Squame discs (in groups of 3) removed from the face repeatedly. TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. TEWL was measured pre-challenge and after 3, 6 and 9 discs have been removed from the face. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: On Day 29 (including Pre-challenge)

,
Interventiong/m^2/hour (Mean)
Pre-challenge Day 29Change from pre-challenge after 3 DiscsChange from pre-challenge after 6 DiscsChange from pre-challenge after 9 Discs
No Treatment14.636.4516.6627.26
Test Product13.104.5811.3420.68

Change From Pre-challenge in Transepidermal Water Loss (TEWL) Measurements of D-Squame Discs Following 4, 8 and 12 Adhesive Discs Removal From Skin of Both Test Product Treated and Untreated Sites on the Forearm on Day 29

A series of D-Squame discs were gently smoothed over the designated D-Squame Areas by applying a uniform pressure for 5 secs with a stamp to ensure consistent adhesion to the skin. Each disc was pulled off the skin with one fluent and decisive movement. There were maximum of 12 D-Squame discs (in groups of 4) removed from each forearm repeatedly. TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. TEWL was measured pre-challenge and after 4, 8 and 12 discs have been removed from the forearms. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: On Day 29 (including Pre-challenge)

,
Interventiong/m^2/hour (Mean)
Pre-challenge Day 29Change from pre-challenge after 4 discsChange from pre-challenge after 8 discsChange from pre-challenge after 12 discs
No Treatment8.333.064.948.46
Test Product6.962.603.355.56

Standardised Area Under Curve (AUC1-29) of Change From Baseline in Corneometry Over Treatment Period

Standardised AUC1-29 was calculated for each participant for change from baseline in corneometry on forearms and face over the treatment period; i.e. up to Day 29 using the trapezoidal rule and dividing by the number of days in the period. Corneometry was used to measure moisture content of stratum corneum using corneometer. The measuring principle is based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. The Corneometer measurements was taken 5 times in total and then an average reading was calculated for each site and time point. An increase in corneometry values indicates an increase in the hydration status of the skin and vice versa. (NCT03216265)
Timeframe: Up to Day 29

,,
InterventionCorneometry units (Mean)
AUC1-29, ForearmAUC1-29, Face
No Treatment2.882.05
Positive Control10.2015.90
Test Product10.8714.03

Standardised Area Under Curve (AUC1-29) of Change From Baseline in Transepidermal Water Loss (TEWL) Over Treatment Period

Standardised AUC1-29 was calculated for each participant for change from baseline in TEWL on forearms and face over the treatment period; i.e. up to Day 29 using the trapezoidal rule and dividing by the number of days in the period. TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 secs, to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 secs were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. (NCT03216265)
Timeframe: Up to Day 29

,,
Interventiong/m^2/hour (Mean)
AUC1-29, ForearmAUC1-29, Face
No Treatment0.82-1.67
Positive Control-0.42-3.21
Test Product-0.30-3.95

Standardised Area Under Curve (AUCday29-34) Calculated Using Change From Baseline in Corneometry Over Regression Period (Days 30, 31, 32, 33 and 34) on the Forearm and Face

Standardised AUCday29-34 was calculated for each participant for change from baseline in corneometry on forearms and face over the regression period using the trapezoidal rule and dividing by the number of days in the period. Corneometry was used to measure moisture content of stratum corneum using corneometer. The measuring principle is based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. The Corneometer measurements was taken 5 times in total and then an average reading was calculated for each site and time point. An increase in corneometry values indicates an increase in the hydration status of the skin and vice versa. (NCT03216265)
Timeframe: Up to Day 34

,,
InterventionCorneometry units (Mean)
Change from baseline in AUCday29-34, forearmChange from baseline in AUCday29-34, face
No Treatment2.650.84
Positive Control4.127.01
Test Product4.877.21

Standardised AUC Calculated Using Change From Day 29 in Corneometry Over Regression Period (Days 30, 31, 32, 33 and 34) on the Forearm and Face

Standardised AUCday29-34 was calculated for each participant for change from day 29 in corneometry on forearms and face over the regression period using the trapezoidal rule and dividing by the number of days in the period. Corneometry was used to measure the moisture content of stratum corneum using corneometer. The measuring principle is based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. The Corneometer measurements were taken 5 times in total and then an average reading was calculated for each site and time point. An increase in corneometry values indicates an increase in the hydration status of the skin and vice versa. (NCT03216265)
Timeframe: Up to Day 34

,,
InterventionCorneometry units (Mean)
Change from Day 29 in AUCday29-34, forearmChange from Day 29 in AUCday29-34, face
No Treatment-1.81-2.99
Positive Control-5.34-11.56
Test Product-6.24-10.04

Reviews

6 reviews available for niacinamide and Skin Aging

ArticleYear
Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention.
    International journal of molecular sciences, 2019, Nov-26, Volume: 20, Issue:23

    Topics: Animals; Energy Metabolism; Genomic Instability; Humans; Immunosuppression Therapy; NAD; Niacinamide

2019
Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety.
    Experimental dermatology, 2019, Volume: 28 Suppl 1

    Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Chemoprevention; Dermatology; DNA Damage;

2019
Nicotinamide and the skin.
    The Australasian journal of dermatology, 2014, Volume: 55, Issue:3

    Topics: Acne Vulgaris; Animals; Autoimmune Diseases; Carcinogenesis; Dermatitis, Atopic; Humans; Keratosis,

2014
Nicotinamide: New Indications in Dermatology.
    Actas dermo-sifiliograficas, 2016, Volume: 107, Issue:9

    Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; Clinical Trials, Phase III as Topi

2016
The Use of Cosmeceuticals in Acne: Help or Hoax?
    American journal of clinical dermatology, 2017, Volume: 18, Issue:2

    Topics: Acne Vulgaris; Complementary Therapies; Contraindications; Cosmeceuticals; Deception; Glycolates; Hu

2017
Topical niacinamide and barrier enhancement.
    Cutis, 2002, Volume: 70, Issue:6 Suppl

    Topics: Administration, Cutaneous; Clinical Trials as Topic; Epidermis; Facial Dermatoses; Humans; Keratolyt

2002

Trials

9 trials available for niacinamide and Skin Aging

ArticleYear
Pigmentation effects of blue light irradiation on skin and how to protect against them.
    International journal of cosmetic science, 2020, Volume: 42, Issue:4

    Topics: Administration, Cutaneous; Adult; Double-Blind Method; Female; Humans; Light; Niacinamide; Placebos;

2020
Randomized controlled study for the anti-aging effect of human adipocyte-derived mesenchymal stem cell media combined with niacinamide after laser therapy.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:6

    Topics: Adipocytes; Aging; Humans; Laser Therapy; Mesenchymal Stem Cells; Niacinamide; Skin Aging

2021
Cosmetic benefit of a biomimetic lamellar cream formulation on barrier function or the appearance of fine lines and wrinkles in randomized proof-of-concept clinical studies.
    International journal of cosmetic science, 2019, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Biomimetics; Cosmetics; Female; Humans; Middle Aged; Niacinamide; Permeabil

2019
Cosmetic benefit of a biomimetic lamellar cream formulation on barrier function or the appearance of fine lines and wrinkles in randomized proof-of-concept clinical studies.
    International journal of cosmetic science, 2019, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Biomimetics; Cosmetics; Female; Humans; Middle Aged; Niacinamide; Permeabil

2019
Cosmetic benefit of a biomimetic lamellar cream formulation on barrier function or the appearance of fine lines and wrinkles in randomized proof-of-concept clinical studies.
    International journal of cosmetic science, 2019, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Biomimetics; Cosmetics; Female; Humans; Middle Aged; Niacinamide; Permeabil

2019
Cosmetic benefit of a biomimetic lamellar cream formulation on barrier function or the appearance of fine lines and wrinkles in randomized proof-of-concept clinical studies.
    International journal of cosmetic science, 2019, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Biomimetics; Cosmetics; Female; Humans; Middle Aged; Niacinamide; Permeabil

2019
Randomized, double-blinded, vehicle-controlled, split-face study to evaluate the effects of topical application of a Gold Silk Sericin/Niacinamide/Signaline complex on biophysical parameters related to skin ageing.
    International journal of cosmetic science, 2015, Volume: 37, Issue:6

    Topics: Administration, Topical; Double-Blind Method; Humans; Niacinamide; Pharmaceutical Vehicles; Sericins

2015
Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide.
    The Journal of dermatology, 2008, Volume: 35, Issue:10

    Topics: Administration, Topical; Adult; Cosmetics; Double-Blind Method; Female; Humans; Middle Aged; Niacina

2008
Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging.
    Journal of cosmetic dermatology, 2009, Volume: 8, Issue:3

    Topics: Adult; Aged; Carnosine; Dimethylpolysiloxanes; Double-Blind Method; Female; Glycerol; Humans; Middle

2009
A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen.
    The British journal of dermatology, 2010, Volume: 162, Issue:3

    Topics: Administration, Topical; Adult; Aged; Cosmetics; Dermatologic Agents; Diterpenes; Emollients; Face;

2010
Niacinamide: A B vitamin that improves aging facial skin appearance.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2005, Volume: 31, Issue:7 Pt 2

    Topics: Administration, Topical; Adult; Dermatologic Agents; Double-Blind Method; Face; Female; Humans; Midd

2005
The clinical anti-aging effects of topical kinetin and niacinamide in Asians: a randomized, double-blind, placebo-controlled, split-face comparative trial.
    Journal of cosmetic dermatology, 2007, Volume: 6, Issue:4

    Topics: Administration, Cutaneous; Adult; Asian People; Dermatologic Agents; Double-Blind Method; Drug Thera

2007

Other Studies

10 other studies available for niacinamide and Skin Aging

ArticleYear
Nicotinamide Prevents UVB- and Oxidative Stress‒Induced Photoaging in Human Primary Keratinocytes.
    The Journal of investigative dermatology, 2022, Volume: 142, Issue:6

    Topics: Humans; Keratinocytes; Niacinamide; Oxidative Stress; Skin Aging; Ultraviolet Rays

2022
Creatine and Nicotinamide Prevent Oxidant-Induced Senescence in Human Fibroblasts.
    Nutrients, 2021, Nov-16, Volume: 13, Issue:11

    Topics: Aged; Cellular Senescence; Creatine; Dermis; Fibroblasts; Humans; Hydrogen Peroxide; Insulin-Like Gr

2021
Formulation and Evaluation of Dermatological Product Containing Niacinamide.
    Advances in experimental medicine and biology, 2021, Volume: 1337

    Topics: Humans; Niacinamide; Skin; Skin Aging; Skin Diseases

2021
Facial Aging Improvement Case Study Using a Novel Combination of Retinol, Niacinamide, and Terminalia Chebula.
    Journal of drugs in dermatology : JDD, 2022, Jul-01, Volume: 21, Issue:7

    Topics: Aging; Humans; Niacinamide; Retinoids; Skin Aging; Terminalia; Tretinoin; Vitamin A

2022
Predictors of female age, health and attractiveness perception from skin feature analysis of digital portraits in five ethnic groups.
    International journal of cosmetic science, 2023, Volume: 45, Issue:5

    Topics: Beauty; Caffeine; Ethnicity; Face; Female; Humans; Niacinamide; Perception; Skin; Skin Aging

2023
A Pilot Study to Evaluate the Efficacy and Tolerability of a Topical Combination Serum for the Improvement of Aged Skin.
    Journal of drugs in dermatology : JDD, 2023, Dec-01, Volume: 22, Issue:12

    Topics: Administration, Cutaneous; Aged; Female; Humans; Hyaluronic Acid; Niacinamide; Pilot Projects; Skin

2023
Combinations of peptides synergistically activate the regenerative capacity of skin cells in vitro.
    International journal of cosmetic science, 2021, Volume: 43, Issue:5

    Topics: Cell Line; Drug Synergism; Gene Expression; Humans; Keratinocytes; Niacinamide; Peptides; Rejuvenati

2021
Nicotinamide Metabolism Modulates the Proliferation/Differentiation Balance and Senescence of Human Primary Keratinocytes.
    The Journal of investigative dermatology, 2019, Volume: 139, Issue:8

    Topics: 3T3 Cells; Acrylamides; Adult; Animals; Cell Differentiation; Cell Proliferation; Cellular Senescenc

2019
Practical application of cellular bioenergetics to the care of aged skin.
    The British journal of dermatology, 2013, Volume: 169 Suppl 2

    Topics: Adult; Cells, Cultured; Collagen Type I; Energy Metabolism; Female; Fibroblasts; Humans; Infant, New

2013
Efficacy and Tolerability of a Skin Brightening/Anti-Aging Cosmeceutical Containing Retinol 0.5%, Niacinamide, Hexylresorcinol, and Resveratrol.
    Journal of drugs in dermatology : JDD, 2016, Jul-01, Volume: 15, Issue:7

    Topics: Administration, Cutaneous; Cosmeceuticals; Drug Combinations; Drug Eruptions; Female; Hexylresorcino

2016